1. Home
  2. PLSE vs PBLS Comparison

PLSE vs PBLS Comparison

Compare PLSE & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

N/A

Current Price

$52.96

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$38.55

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLSE
PBLS
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.6B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
PLSE
PBLS
Price
$52.96
$38.55
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$22.00
N/A
AVG Volume (30 Days)
491.4K
351.6K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$25.56
52 Week High
$55.37
$41.49

Technical Indicators

Market Signals
Indicator
PLSE
PBLS
Relative Strength Index (RSI) 67.27 56.63
Support Level $24.27 $37.88
Resistance Level N/A $41.49
Average True Range (ATR) 3.51 1.93
MACD -0.20 -0.28
Stochastic Oscillator 64.41 31.28

Price Performance

Historical Comparison
PLSE
PBLS

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: